Companies › Lyell Immunopharma
2 active drug programs in 3 registered trials: 2 Phase 1, 1 Phase 3; Oncology; next expected readout Jun 2028.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Rondecabtagene autoleucel (ronde-cel) Dual-targeting CAR T-cell therapy targeting CD19 and CD20 | CD19, CD20 | Phase 3 | Large B-cell Lymphoma; Relapsed Non-Hodgkin Lymphoma | Dec 2028 |
| LYL273 CAR-T cell therapy (autologous T cells with chimeric antigen receptor) | – | Phase 1 | Colorectal Cancer | Jun 2028 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05319314 | LYL273 | Phase 1 | Colorectal Cancer | Oncology | Jun 2028 |
| NCT05826535 | Rondecabtagene autoleucel (ronde-cel) | Phase 1 | Relapsed Non-Hodgkin Lymphoma | Oncology | Dec 2028 |
| NCT07188558 | Rondecabtagene autoleucel (ronde-cel) | Phase 3 | Large B-cell Lymphoma | Oncology | Dec 2029 |
Cash and short-term investments of $177m on 2026-09-30; operating cash outflow about $144m a year; runway about 15 months at that burn, to Dec 2027; 0 of 1 coming phase 2-3 readouts fall inside that runway
Press releases filed as 8-K in the last year:
Held by 2 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.
Kura Oncology ALX Oncology Immuneering ADC Therapeutics Eikon Therapeutics
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.